[Adverse effects of alpha-glucosidase inhibitors].
Sakaguchi
Kazuhiko
K
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine.
Kasuga
Masato
M
D017485:1-Deoxynojirimycin / Q000009:adverse effects / Q000031:analogs & derivatives; D020909:Acarbose / Q000009:adverse effects; D004066:Digestive System Diseases / Q000139:chemically induced*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D022124:Hyperammonemia / Q000139:chemically induced*; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D050112:Imino Pyranoses / Q000009:adverse effects; D007294:Inositol / Q000009:adverse effects / Q000031:analogs & derivatives
D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D050112:Imino Pyranoses; C045621:miglitol; D017485:1-Deoxynojirimycin; D007294:Inositol; C102817:voglibose; D020909:Acarbose